Citadel Advisors
SCPS

Citadel Advisors’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Citadel Advisors’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,897
Closed -$34K – 15074
2021
Q4 		$34K Buy
+20,897
New +$63.3K ﹤0.01% 13432

Other funds holding SCPS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MRCM
M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's SCPS Position: Q1 2022 in Review

Citadel Advisors sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q1 2022, closing a stake of 20,897 shares — an estimated $34K sold.

Citadel Advisors first reported a position in SCPS in Q4 2021 and held it in 1 quarter. The position peaked at $34K in Q4 2021. 19 funds tracked by Wall St. Rank hold SCPS as of Q1 2022.

  • Citadel Advisors reported no remaining Scopus BioPharma Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 20,897 Scopus BioPharma Inc. Common Stock shares in Q1 2022, an estimated $34K.
  • Citadel Advisors first reported a position in Scopus BioPharma Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Citadel Advisors's Scopus BioPharma Inc. Common Stock position peaked at $34K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.